Bellicum pharmaceuticals, inc. (BLCM)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net income (loss)

-70,373

-112,477

-110,716

-102,485

-99,724

-98,036

-92,734

-92,364

-92,646

-91,779

-89,799

-84,087

-76,139

-69,241

-66,151

-61,840

-55,865

-48,548

-105,998

-96,686

-89,433

-83,965

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

6,525

7,338

8,732

10,778

12,355

13,824

14,206

14,193

13,810

13,569

13,311

12,708

12,636

12,337

11,714

10,956

9,985

8,409

6,603

4,390

2,324

911

0

0

0

Depreciation and amortization expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and private placement option liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

-

-

-

-

-

-

-

5,116

4,208

3,564

3,211

3,003

2,625

2,306

2,049

1,775

1,466

1,199

951

721

704

667

0

0

0

Amortization of discount on investment securities, net

12

30

53

61

15

-94

-206

-306

-332

-302

-304

-322

-416

-539

-645

-744

-757

-573

0

0

0

-

-

-

-

Amortization of right-of-use assets

1,104

1,331

996

636

312

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of lease liability

-229

-804

-512

-206

85

276

229

184

137

102

90

79

99

119

0

0

0

-

-

-

-

-

-

0

0

Amortization of lease liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Amortization of deferred issuance costs

881

885

885

883

885

886

833

836

829

774

751

652

558

422

275

150

28

0

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Changes in operating assets and liabilities:
Accounts receivable, interest and other receivables

-901

-606

-210

193

526

589

70

69

137

-14

163

-107

-77

-106

-83

-80

267

142

-833

-1,302

-1,179

-448

0

0

0

Prepaid expenses and other assets

209

1,096

616

1,137

323

-1,070

83

-128

-161

930

282

558

240

-885

-96

-134

1,053

1,067

1,981

2,307

994

1,068

0

0

0

Accounts payable

-228

-1,131

-570

530

-21

460

-1,033

-730

-590

-512

496

470

70

931

84

166

659

897

-158

276

671

659

0

0

0

Accrued liabilities and other

-3,027

-2,300

2,534

2,941

889

2,197

769

-526

-663

-3,667

-2,426

-1,089

-1,617

1,336

2,984

3,578

4,203

2,778

2,225

336

-330

225

0

0

0

Deferred revenue

-2,467

-2,983

-2,322

-2,511

-1,482

-1,120

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred manufacturing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

176

0

0

0

Other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-69,268

-77,569

-85,236

-83,128

-80,666

-74,782

-67,204

-68,062

-69,204

-72,984

-74,650

-68,514

-61,656

-50,441

-48,088

-44,125

-39,938

-35,726

-73,740

-67,249

-61,115

-57,308

0

0

0

Cash flows from investing activities:
Purchases of investment securities

-

-

-

-

-

-

69,253

59,332

49,720

54,895

43,443

38,596

23,748

33,276

48,665

50,730

122,664

101,649

0

0

0

-

-

-

-

Cash flows from investing activities:
Proceeds from sale of investment securities

31,216

49,379

64,352

69,231

72,250

71,362

70,440

62,527

59,587

63,737

62,317

65,710

52,790

42,548

38,641

34,148

31,800

20,617

0

0

0

-

-

-

-

Purchases of property and equipment

428

522

850

1,113

1,332

1,617

2,901

5,616

10,957

12,134

11,987

10,226

6,520

7,220

6,611

7,242

6,781

5,421

5,000

3,428

1,715

804

0

0

0

Net cash (used in) provided by investing activities

30,788

48,857

54,808

41,240

17,895

10,410

-1,675

-2,382

-1,051

-3,253

6,887

16,888

22,522

2,052

-16,635

-23,824

-97,645

-86,453

-76,357

-74,720

-1,715

-804

0

0

0

Cash flows from financing activities:
Payment on debt

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in a public offering, net

4,352

8,977

9,172

9,172

69,485

64,860

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

6

76

380

391

2,542

3,300

3,029

3,174

1,729

1,486

1,664

1,785

1,245

773

1,044

685

593

482

-212

82

2

0

0

0

0

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Payments of Debt Issuance Costs

-

-

-

-

-

-

-

-

-

150

75

75

75

199

199

199

199

0

0

0

0

-

-

-

-

Payment on financing lease obligations

56

47

38

30

32

31

30

28

26

23

21

18

16

15

9

11

7

4

0

0

0

-

-

-

-

Proceeds from issuance of Series B preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Payment of issuance costs on common stock

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-1

7

10,726

14,250

14,250

14,242

0

0

0

Proceeds from exercise of common warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from line of credit or notes payable or debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Payments on line of credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash (used in) provided by financing activities

67,384

74,088

74,659

9,485

71,975

68,109

70,126

70,273

3,969

78,486

76,484

81,608

81,355

20,928

20,930

15,852

15,735

818

180,651

231,458

231,119

238,546

0

0

0

Effect of exchange rate changes on cash

-269

-228

-139

-116

-70

-98

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents, and restricted cash

28,635

45,148

44,092

-32,519

9,134

3,639

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-

-

-

-

-

-

-

-

-

-

-

-

42,221

-27,461

0

0

0

-

-

-

-

-

-

-

-

NET CHANGE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Supplemental cash flow information:
Cash paid during the period for interest

3,136

3,201

3,185

3,411

3,098

3,025

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

0

0

0

0

-

-

-

-

Non-cash investing and financing activities:
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payables and accrued liabilities

-5

0

-28

5

-187

27

-768

-2,112

-2,625

872

4,162

5,420

6,689

3,533

1,205

1,258

699

139

0

0

0

-

-

-

-

Conversion of redeemable preferred stock into common stock

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of property and equipment, net to assets held for sale

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued debt issuance costs

-

-

-

-

-

-

-

-

-

3,045

695

869

869

1,390

1,390

1,216

1,216

0

0

0

0

-

-

-

-

Accrued issuance costs for public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Capital lease obligations incurred for equipment

-

-

-

-

-

-

-

-

-

23

35

35

278

46

104

169

154

135

0

0

0

-

-

-

-

Preferred stock dividends paid in common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,196

0

0

0